Measles

Modine Introduces VidaShield™ UV24 Active Air Disinfection System to K-12 School Markets

Retrieved on: 
Wednesday, December 6, 2023

RACINE, Wis., Dec. 6, 2023 /PRNewswire/ -- Modine (NYSE: MOD), a technology and indoor air quality leader in the HVAC industry, is now offering the VidaShield™ UV24 Active Air Disinfection System product line to the K-12 school market. This innovative solution will further help equip schools with the necessary tools to combat airborne pathogens.

Key Points: 
  • Innovative 24/7 air disinfection system combines germicidal irradiation with air circulation fans to help improve IAQ in schools.
  • RACINE, Wis., Dec. 6, 2023 /PRNewswire/ -- Modine (NYSE: MOD), a technology and indoor air quality leader in the HVAC industry, is now offering the VidaShield™ UV24 Active Air Disinfection System product line to the K-12 school market.
  • VidaShield™ UV24 is a fast, continuous air disinfection system that combines an ultraviolet germicidal irradiation (UVGI) chamber and air circulating fans with an optional overhead ceiling light, making it convenient for schools, universities and daycare centers.
  • For more information about the VidaShield™ UV24 Active Air Disinfection System, please visit https://vidashield.com/ .

Edgewell Personal Care Recognized for Contribution to the American Red Cross Ready 365 Giving Circle

Retrieved on: 
Tuesday, November 28, 2023

SHELTON, Conn., Nov. 28, 2023 /PRNewswire/ -- Edgewell Personal Care Company (NYSE: EPC), based in Shelton, CT, is partnering with the American Red Cross to support Red Cross Disaster Relief and International Services as part of the Ready 365 Giving Circle, and in pursuit of Edgewell's core purpose, values and behaviors.

Key Points: 
  • SHELTON, Conn., Nov. 28, 2023 /PRNewswire/ -- Edgewell Personal Care Company (NYSE: EPC), based in Shelton, CT, is partnering with the American Red Cross to support Red Cross Disaster Relief and International Services as part of the Ready 365 Giving Circle, and in pursuit of Edgewell's core purpose, values and behaviors.
  • Red Cross services are provided to those in need of assistance at no cost and regardless of income through the generosity of Red Cross donors.
  • "To fulfill our lifesaving mission, the Red Cross relies on the generosity of our volunteers and donors," said Richard Branigan, Interim CEO, American Red Cross Connecticut and Rhode Island Region.
  • Rod Little, CEO of Edgewell Personal Care stated, "We at Edgewell couldn't be more proud to support the American Red Cross.

Charles IT Founder & CEO, Foster Charles, Helps Business Leaders Explore the Impact of AI Adoption in the Workplace

Retrieved on: 
Monday, November 20, 2023

STAMFORD, Conn., Nov. 20, 2023 /PRNewswire-PRWeb/ -- With the exception of those who never use computers or smartphones and refrain from conducting business online or over the phone —we all use AI. From online banking, help desk support, online investing, and search engines to internet streaming platforms (Netflix or Spotify, anyone?!), online shopping, and even your doctor's office, AI is woven into the fabric of our lives.

Key Points: 
  • With so much recent discussion around ChatGPT and other AI learning models, Charles IT Founder & CEO, Foster Charles, deconstructs the topic to help business leaders better understand AI's role in our lives.
  • It allows businesses to do what they do faster, more efficiently, and, in many cases, with far less risk.
  • Whether you are an AI champion or an end-user, it is essential to consider the implications of widespread AI adoption.
  • The AI needs data to learn, of course, so more information is valuable as it helps the predictive AI engine deliver better results.

Bioxytran Gets Broad Patent Coverage on 60+ Viruses

Retrieved on: 
Tuesday, October 24, 2023

BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.

Key Points: 
  • The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
  • This patent represents what we believe is a new direction in the evolution of antiviral therapies that originally started during the HIV epidemic.
  • This pending patent with its broad claims also shows the Company is well-positioned with respect to its intellectual property portfolio.
  • This patent covers some of the largest indications in virology and includes viruses like COVID-19, influenza, herpes, Epstein-Barr, shingles, hepatitis C, measles, mumps, and rubella.

Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)

Retrieved on: 
Thursday, October 19, 2023

The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.

Key Points: 
  • The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.
  • The HD-MAP, upon which vaccines are ‘printed’ and dried, also provides storage and distribution benefits due to reduced cold chain requirements generally associated with vaccines delivered by needle and syringe.
  • Vaxxas is advancing a robust pipeline of pre-clinical and clinical stage HD-MAP vaccine candidates and has recently concluded multiple Phase I clinical studies.
  • The current Vaxxas pipeline targets COVID-19, seasonal and pandemic influenza, typhoid, measles and rubella, and cancer.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Global Adult Vaccines Market Research Report 2023: Market to Surpass $25 Billion by 2027 - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023

Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.

Key Points: 
  • Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.
  • The adult vaccines market research report is an invaluable resource, offering a wealth of statistics on the adult vaccines market, including global market size, regional distributions, insights into market competitors with their respective market shares, comprehensive segmentation of the adult vaccines market, prevailing market trends, and promising opportunities.
  • These alarming statistics underscore the pivotal role of adult vaccines in curbing the spread of contagious diseases and substantiate the burgeoning growth of the adult vaccines market.
  • The adult vaccines market encompasses the sales of mRNA vaccines and viral vector vaccines.

Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries

Retrieved on: 
Wednesday, September 13, 2023

Takeda ( TSE:4502/NYSE:TAK ) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries.
  • Takeda expects that Global CSR Program’s new five partnerships will bring its reach to 25.2 million people in 92 countries by 2028.
  • There are no quick fixes to global health challenges, which are complex, multi-dimensional and context dependent.
  • Health Information Systems: Developed, enhanced, or implemented 49 digital solutions, platforms, or tools to support data-informed health planning and health decision-making.

Global Vaccine Market Anticipated to Reach $92.32 Billion by 2028: Players Include GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer and CSL - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023

Influenza vaccines reduce the risk of illness by 40% to 60% worldwide, including in the United States.

Key Points: 
  • Influenza vaccines reduce the risk of illness by 40% to 60% worldwide, including in the United States.
  • Emerging markets are witnessing a surge in demand for influenza vaccines due to high disease prevalence and limited access to vaccination.
  • Combo Vaccines: Combination vaccines that provide protection against multiple diseases with a single shot are gaining popularity.
  • Government initiatives, growing awareness of the benefits of vaccination, and advancements in vaccine technology have fueled their growth.